HYPRF (HYPRF)

Shares of Hyperfine, Inc. (NASDAQ:HYPR – Get Free Report) have received an average rating of “Hold” from the six analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three ...

Hyperfine (NASDAQ:HYPR – Get Free Report) and CardioGenics (OTCMKTS:CGNH – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, ...

Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and +14.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Hyperfine’s Q1 2026 revenue rose to $3.9M as device sales more than doubled, while net loss narrowed to $8.6M. Cash reached $41.3M after drawing a $15M term loan.

Shares of Hyperfine (NASDAQ:HYPR) gained 4% in premarket trading on Tuesday after the company announced that it is expected to be added to both the Russell 3000 Index and the Russell 2000 Index. Russell inclusion set to take effect after June reconstitutionThe medical technology company said ...